Statins decrease programmed death-ligand 1 (PD-L1) by inhibiting AKT and β-catenin signaling

WJ Lim, M Lee, Y Oh, XQ Fang, S Lee, CH Lim, J Park… - Cells, 2021 - mdpi.com
Retrospective observational studies have reported that statins improve clinical outcomes in
patients previously treated with programmed cell death protein 1 (PD-1)-targeting
monoclonal antibodies for malignant pleural mesothelioma (MPM) and advanced non-small
cell lung cancer (NSCLC). In multiple mouse cancer models, de novo synthesis of
mevalonate and cholesterol inhibitors was found to synergize with anti-PD-1 antibody
therapy. In the present study, we investigated whether statins affect programmed death …

[引用][C] Statin Decrease Programmed Death-Ligand (PD-L1) by Inhibiting AKT and β-Catenin Signaling

LIM Chang-Hoon, F Xue-Quan… - 한국생물공학회학술 …, 2023 - dbpia.co.kr
Retrospective observational studies have reported that statins improve clinical outcomes in
patients previously treated with programmed cell death protein 1 (PD-1) targeting
monoclonal antibodies for malignant pleural mesothelioma (MPM) and advanced non-small-
cell lung cancer (NSCLC). In multiple mouse cancer models, de novosynthesis of
mevalonate and cholesterol inhibitors was found to synergize with anti-PD-1 antibody
therapy. In the present study, we investigated whether statins affect programmed death …
以上显示的是最相近的搜索结果。 查看全部搜索结果